InterVenn Biosciences | Clinical Glycoproteomics
InterVenn Biosciences pioneers AI- and ML-powered glycoproteomic analysis through its GlycoVision platform, enabling high-throughput biomarker discovery from blood samples. Co-founded in 2017 by Nobel Laureate Carolyn Bertozzi, Dr. Carlito Lebrilla, and Aldo Carrascoso, the company serves biopharma partners and clinicians with diagnostic applications including GlycoKnow Ovarian for ovarian cancer detection.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountAug 2021
Nov 2020
Dec 2018
Create a free account to see which investors have funded this company.
Create Free Account
Next-gen Medicare Advantage insurance plan with AI-forward medical group delivering quality and s...
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
OpenAI is an AI research and deployment company dedicated to ensuring that general-purpose artifi...
